Article Figures & Data
Figures
- Figure 1.
Maximum PSA response rate of patients. A) Waterfall plot of maximum PSA response rate in the relative dose intensity (RDI) ≤60% group. B) Waterfall plot of maximum PSA response rate in the RDI >60% group.
- Figure 2.
Oncological outcomes of patients. A) Kaplan-Meier curves of progression-free survival (PFS) after initiating cabazitaxel treatment stratified by relative dose intensity (RDI) >60% and RDI ≤60%. The solid and dotted lines indicate a PFS of patients in the RDI >60% and RDI ≤60% groups, respectively. The median PFS of patients in the RDI >60% and RDI ≤60% groups were 5 months and 2 months, respectively (p<0.01). B) Kaplan-Meier curves of overall survival (OS) after initiating cabazitaxel treatment stratified by RDI >60% and RDI ≤60%. The solid and dotted lines indicate OS of patients in the RDI >60% and RDI ≤60% groups, respectively. The median OS of patients in the RDI >60% and RDI ≤60% groups were 15 months and 6 months, respectively (p<0.01).
Tables
In this issue
Jump to section
Related Articles
Cited By...
- Risk Factors and Clinical Significance of Grade >=3 Neutropenia During the First Cycle of Cabazitaxel Therapy With Primary Pegfilgrastim Prophylaxis in Metastatic Castration-resistant Prostate Cancer
- Patients Diagnosed With Metastatic Castration-sensitive Prostate Cancer and High Serum Lactate Dehydrogenase Levels Did Not Receive an Adequate Dose of Cabazitaxel
- Impact of Novel Agents on Patient Characteristics, Treatment Patterns, and Outcomes in Patients With Metastatic Castration-resistant Prostate Cancer